Back to Journals » Therapeutics and Clinical Risk Management » Volume 8

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis

Authors Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O'Regan C, Mills EJ

Received 10 January 2012

Accepted for publication 3 February 2012

Published 9 March 2012 Volume 2012:8 Pages 105—130

DOI https://doi.org/10.2147/TCRM.S29830

Review by Single-blind

Peer reviewer comments 2

Curtis L Cooper1, Eric Druyts2, Kristian Thorlund3, Jean B Nachega4, Antoine C El Khoury5, Christopher O'Regan6, Edward J Mills2,3
1Division of Infectious Diseases, Faculty of Medicine, 2Faculty of Health Sciences, University of Ottawa, Ottawa, 3Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; 4Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, 5Merck and Co, Inc, Whitehouse Station, NJ, 6Merck Sharp and Dohme Ltd, Hoddesdon, Hertfordshire, United Kingdom

Background: The aim of this study was to examine the relative efficacy and safety of boceprevir and telaprevir, when used in combination with pegylated interferon alpha and ribavirin, using an indirect comparison meta-analysis.
Methods: Published phase II and phase III randomized placebo-controlled trials examining the efficacy of boceprevir and telaprevir in chronic hepatitis C virus genotype 1 infected adult populations were included. The primary outcomes were sustained virologic response, relapse, and discontinuation of all study drugs. Secondary outcomes included the adverse events of anemia, neutropenia, rash, and pruritus.
Results: Four boceprevir trials and six telaprevir trials were included. No significant differences were observed for sustained virologic response among either naïve (relative risk [RR] 1.14, 95% confidence interval [CI] 0.93–1.37, P = 0.20) or experienced patients (RR 0.81, 95% CI 0.52–1.23, P = 0.30). Similarly, for relapse among naïve (RR 0.80, 95% CI 0.18–3.45, P = 0.77) and experienced patients (RR 1.71, 95% CI 0.90–3.24, P = 0.10), or discontinuation of therapy for naïve (RR 0.80, 95% CI 0.28–2.29, P = 0.72) and experienced patients (RR 0.88, 95% CI 0.69–1.12, P = 0.30). Telaprevir was more likely to be associated with rash and pruritus, and boceprevir was more likely to be associated with neutropenia in certain patient populations.
Conclusion: Boceprevir and telaprevir appear comparable in terms of sustained virologic response, relapse, or discontinuation of therapy for patients treated with standard-dose therapy durations and response-guided therapy durations.

Keywords: direct-acting antivirals, boceprevir, telaprevir, hepatitis C, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Increased mortality among HIV-positive men on antiretroviral therapy: survival differences between sexes explained by late initiation in Uganda

Kanters S, Nansubuga M, Mwehire D, Odiit M, Kasirye M, Musoke W, Druyts E, Yaya S, Funk A, Ford N, Mills EJ

HIV/AIDS - Research and Palliative Care 2013, 5:111-119

Published Date: 29 May 2013

Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis

Thorlund K, Druyts E, Aviña-Zubieta JA, Mills EJ

Biologics: Targets and Therapy 2012, 6:417-427

Published Date: 3 December 2012

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection

Thorlund K, Druyts E, El Khoury AC, Mills EJ

ClinicoEconomics and Outcomes Research 2012, 4:349-359

Published Date: 16 November 2012

Predictive value of CD4 cell count nadir on long-term mortality in HIV-positive patients in Uganda

Bray S, Gedeon J, Hadi A, Kotb A, Rahman T, Sarwar E, Savelyeva A, Sévigny M, Bakanda C, Birungi J, Chan K, Yaya S, Deonandan R, Mills EJ

HIV/AIDS - Research and Palliative Care 2012, 4:135-140

Published Date: 17 August 2012

Multiple treatment comparison meta-analyses: a step forward into complexity

Mills E, Bansback N, Ghement I, Thorlund K, Kelly S, Puhan M, Wright J

Clinical Epidemiology 2011, 3:193-202

Published Date: 27 May 2011

Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis

Mills EJ, Druyts E, Ghement I, Puhan MA

Clinical Epidemiology 2011, 3:107-129

Published Date: 28 March 2011

Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment

Christopher Au-Yeung, Steve Kanters, Erin Ding, et al

Clinical Epidemiology 2011, 3:21-29

Published Date: 19 January 2011

Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis

Oghenowede Eyawo, Jean Nachega, Pierre Lefebvre, et al

Clinical Ophthalmology 2009, 3:447-456

Published Date: 31 July 2009

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010